微小RNA-301A通过抑制BTG1促进肠道炎症及结肠炎相关癌症发展
研究比较了153例不同活动期IBD患者、6例结肠炎相关癌症患者和35名健康对照的肠上皮细胞,发现MIR301A表达升高而BTG1表达降低。小鼠实验表明敲除MIR301A可抵抗DSS诱导的结肠炎和肿瘤形成,过表达BTG1则减轻结肠炎严重程度。作者认为降低结肠组织中MIR301A水平可能用于治疗IBD和结肠炎相关癌症。
要点
- 活动期IBD和结肠炎相关癌症患者肠上皮细胞中MIR301A表达升高,BTG1 mRNA降低且与MIR301A呈负相关。
- MIR301A敲除小鼠对DSS诱导的结肠炎抵抗,结肠组织IL1β、IL6、IL8和肿瘤坏死因子水平低于对照小鼠。
- 表达抗MIR301A的SW480细胞在裸鼠中形成的移植瘤少于对照载体细胞。
核心结论
- 活动期IBD患者肠上皮细胞中MIR301A水平升高,MIR301A通过降低BTG1表达减少上皮完整性并促进小鼠结肠炎症和肿瘤发生。
- 作者认为可开发降低结肠组织中MIR301A水平的策略来治疗IBD和结肠炎相关癌症患者。
研究设计与样本
- 研究纳入中国上海153例不同IBD活动期患者、6例结肠炎相关癌症患者和35名健康对照,检测肠上皮细胞中MIR301A和BTG1表达。
- 使用表达MIR301A的慢病毒转染人结肠癌细胞系HCT-116和SW480,检测细胞因子和紧密连接蛋白表达。
- 构建MIR301A基因敲除小鼠和表达BTG1转基因的小鼠,用DSS诱导结肠炎、用氧化偶氮甲烷诱导结直肠癌发生,进行组织学和免疫组化分析并计数肿瘤结节和测量肿瘤大小。
- 将表达MIR301A转基因的SW480细胞在裸鼠中培养为移植瘤。
主要发现
- 与对照相比,IBD和结肠炎相关癌症患者肠上皮细胞中MIR301A表达升高。
- MIR301A敲除小鼠在DSS给药后抵抗结肠炎发生,其结肠组织IL1β、IL6、IL8和肿瘤坏死因子水平低于对照小鼠。
- MIR301A敲除小鼠结肠组织上皮屏障完整性增加,氧化偶氮甲烷给药后形成的肿瘤少于对照小鼠。
- 表达转基因MIR301A的人肠上皮细胞下调钙黏蛋白1(CDH1)表达。
- 活动期IBD患者炎症黏膜中BTG1 mRNA水平较对照降低,且与MIR301A水平呈负相关;表达MIR301A转基因的人结肠癌细胞系增殖增加、通透性增加且CDH1表达降低;BTG1转基因小鼠DSS给药后结肠炎较对照轻;表达抗MIR301A的SW480细胞在裸鼠中形成的移植瘤少于对照载体细胞。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Intestinal tissues from patients with inflammatory bowel disease (IBD) and colorectal cancer have increased expression of microRNA-301a (MIR301A) compared with tissues from patients without IBD. We studied the mechanisms of MIR301A in the progression of IBD in human tissues and mice. METHODS: We isolated intestinal epithelial cells (IECs) from biopsy samples of the colon from 153 patients with different stages of IBD activity, 6 patients with colitis-associated cancer (CAC), and 35 healthy individuals (controls), enrolled in the study in Shanghai, China. We measured expression of MIR301A and BTG anti-proliferation factor 1 (BTG1) by IECs using quantitative reverse-transcription polymerase chain reaction. Human colon cancer cell lines (HCT-116 and SW480) were transfected with a lentivirus that expresses MIR301A; expression of cytokines and tight junction proteins were measured by quantitative reverse transcription polymerase chain reaction, flow cytometry, and immunofluorescence staining. We generated mice with disruption of the microRNA-301A gene (MIR301A-knockout mice), and also studied mice that express a transgene-encoding BTG1. Colitis was induced in knockout, transgenic, and control (C57BL/B6) mice by administration of dextran sulfate sodium (DSS), and mice were given azoxymethane to induce colorectal carcinogenesis. Colons were collected and analyzed histologically and by immunohistochemistry; tumor nodules were counted and tumor size was measured. SW480 cells expressing the MIR301A transgene were grown as xenograft tumors in nude mice. RESULTS: Expression of MIR301A increased in IECs from patients with IBD and CAC compared with controls. MIR301A-knockout mice were resistant to the development of colitis following administration of DSS; their colon tissues expressed lower levels of interleukin 1β (IL1β), IL6, IL8, and tumor necrosis factor than colons of control mice. Colon tissues from MIR301A-knockout mice had increased epithelial barrier integrity and formed fewer tumors following administration of azoxymethane than control mice. Human IECs expressing transgenic MIR301A down-regulated expression of cadherin 1 (also called E-cadherin or CDH1). We identified BTG1 mRNA as a target of MIR301A; levels of BTG1 mRNA were reduced in inflamed mucosa from patients with active IBD compared with controls. There was an inverse correlation between levels of BTG1 mRNA and levels of MIR301A in inflamed mucosal tissues from patients with active IBD. Human colon cancer cell lines that expressed a MIR301A transgene increased proliferation; they had increased permeability and decreased expression of CDH1 compared with cells transfected with a control vector, indicating reduced intestinal barrier function. BTG1 transgenic mice developed less severe colitis than control mice following administration of DSS. SW480 cells expressing anti-MIR301A formed fewer xenograft tumors in nude mice than cells expressing a control vector. CONCLUSIONS: Levels of MIR301A are increased in IECs from patients with active IBD. MIR301A reduces expression of BTG1 to reduce epithelial integrity and promote inflammation in mouse colon and promotes tumorigenesis. Strategies to decrease levels of MIR301A in colon tissues might be developed to treat patients with IBD and CAC.
引用
- He C, Yu T, Shi Y, et al. MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1. Gastroenterology. 2017. PMID: 28193514. doi:10.1053/j.gastro.2017.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。